Early Experiences With Nirsevimab: Perspectives From Newborn Hospitalists

BACKGROUND

RSV, the leading cause of bronchiolitis, primarily affects young children. According to the Centers for Disease Control and Prevention (CDC), RSV accounts for an annual 2.1 million outpatient visits, 58,000-80,000 hospitalizations, and 100-300 deaths in children <5 years old.1 Infants <6 months of age are at greatest risk of hospitalization, with the highest morbidity and costs in infants born prematurely.2,3 In addition, RSV infections lead to economic productivity loss and heightened parental emotional stress.4 Along with Coronavirus Disease 2019 (COVID-19) and influenza, respiratory season can significantly strain the healthcare system, as was seen and experienced by many pediatric hospitalists during the 2022-2023 "tripledemic."